IL97709A - Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis - Google Patents

Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Info

Publication number: IL97709A
Authority: IL; Israel
Prior art keywords: multiple sclerosis; directed; medicament; preparation; treatment
Prior art date: 1990-03-30

Application number

IL9770991A

Other languages

English (en)

Other versions

IL97709A0 (en

Original Assignee

Brigham & Womens Hospital

Autoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1991-03-28

Publication date

2005-05-17

1991-03-28 Application filed by Brigham & Womens Hospital, Autoimmune Inc filed Critical Brigham & Womens Hospital

1992-06-21 Publication of IL97709A0 publication Critical patent/IL97709A0/xx

2005-05-17 Publication of IL97709A publication Critical patent/IL97709A/xx

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
238000009007 Diagnostic Kit Methods 0.000 abstract 1
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
102000047918 Myelin Basic Human genes 0.000 abstract 1
101710107068 Myelin basic protein Proteins 0.000 abstract 1
230000002238 attenuated effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
102000054064 human MBP Human genes 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
-1 vaccines Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pathology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)

IL9770991A 1990-03-30 1991-03-28 Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis IL97709A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US50255990A	1990-03-30	1990-03-30

Publications (2)

Publication Number	Publication Date
IL97709A0 IL97709A0 (en)	1992-06-21
IL97709A true IL97709A (en)	2005-05-17

Family

ID=23998362

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL9770991A IL97709A (en)	1990-03-30	1991-03-28	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
IL165071A IL165071A (en)	1990-03-30	1991-03-28	A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
IL16507104A IL165071A0 (en)	1990-03-30	2004-11-07	The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL165071A IL165071A (en)	1990-03-30	1991-03-28	A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
IL16507104A IL165071A0 (en)	1990-03-30	2004-11-07	The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis

Country Status (13)

Country	Link
EP (1)	EP0522091B9 (de)
JP (1)	JPH05507911A (de)
AT (1)	ATE210721T1 (de)
AU (1)	AU651350B2 (de)
BR (1)	BR9106303A (de)
CA (1)	CA2078549C (de)
DE (1)	DE69132863T2 (de)
DK (1)	DK0522091T5 (de)
ES (1)	ES2169021T3 (de)
HU (1)	HU217847B (de)
IL (3)	IL97709A (de)
NO (1)	NO308611B1 (de)
WO (1)	WO1991015225A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207645B1 (en)	1989-03-21	2001-03-27	The Immune Response Corporation	Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en)	1989-03-21	2001-04-24	The Immune Response Corporation	Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
EP0725277A3 (de) *	1990-05-01	1996-12-04	Univ Leland Stanford Junior	Variable Transskripte von T-Zellen als Marker für Krankheiten
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH06507384A (ja) *	1991-01-22	1994-08-25	ザ　イミューン　レスポンス　コーポレイション	特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en)	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
AU3418893A (en) *	1991-12-24	1993-07-28	Immune Response Corporation, The	Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5891435A (en) *	1993-04-16	1999-04-06	Research Corporation Technologies, Inc.	Methods and compositions for delaying or preventing the onset of autoimmune disease
AU2950195A (en) *	1994-07-01	1996-01-25	Connective Therapeutics Inc.	Methods for diagnosing an immune-related disease and choosing an immune-related therapy
BR9509438A (pt) *	1994-10-25	1997-12-23	Immulogic Pharma Corp	Composições e tratamento para a esclerose múltipla
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
IL114458A0 (en) *	1995-07-05	1995-11-27	Yeda Res & Dev	Therapeutic preparations for treatment of T cell mediated diseases
US20020009448A1 (en) *	1997-09-19	2002-01-24	Leslie P. Weiner	T-cell vaccination for the treatment of multiple sclerosis
WO2001089557A2 (en)	2000-05-24	2001-11-29	The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services	Methods for preventing strokes by inducing tolerance to e-selectin
DK1918298T3 (da) *	2000-08-21	2010-11-29	Apitope Technology Bristol Ltd	Peptid
US7658926B2 (en)	2001-09-14	2010-02-09	Opexa Pharmaceuticals, Inc.	Autologous T-cell vaccines materials and methods
US7744893B2 (en)	2002-06-05	2010-06-29	Baylor College Of Medicine	T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
DE60330780D1 (de) *	2002-06-05	2010-02-11	Opexa Pharmaceuticals Inc	Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren
US7695713B2 (en)	2002-08-08	2010-04-13	Baylor College Of Medicine	Isolation and identification of T cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2072356A1 (en) *	1989-12-29	1991-06-30	James L. Urban	Diagnosis and treatment of diseases

1991
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en not_active Ceased
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 EP EP91910085A patent/EP0522091B9/de not_active Expired - Lifetime
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant

Also Published As

Publication number	Publication date
DE69132863D1 (de)	2002-01-24
DE69132863T2 (de)	2002-06-20
IL165071A0 (en)	2005-12-18
HUT63334A (en)	1993-08-30
IL97709A0 (en)	1992-06-21
HU9203100D0 (en)	1992-12-28
JPH05507911A (ja)	1993-11-11
DK0522091T5 (da)	2008-06-23
CA2078549C (en)	2006-07-11
EP0522091B9 (de)	2007-11-21
AU651350B2 (en)	1994-07-21
EP0522091A1 (de)	1993-01-13
HU217847B (hu)	2000-04-28
AU7898991A (en)	1991-10-30
ES2169021T3 (es)	2002-07-01
BR9106303A (pt)	1993-04-13
WO1991015225A1 (en)	1991-10-17
NO923778L (no)	1992-11-16
NO923778D0 (no)	1992-09-29
EP0522091A4 (en)	1993-05-26
NO308611B1 (no)	2000-10-02
DK0522091T3 (da)	2002-04-08
IL165071A (en)	2008-06-05
ATE210721T1 (de)	2001-12-15
EP0522091B1 (de)	2001-12-12
CA2078549A1 (en)	1991-10-01

Legal Events

Date	Code	Title
2006-02-05	KB	Patent renewed
2009-09-15	KB	Patent renewed
2011-12-29	EXP	Patent expired

Publication	Publication Date	Title
IL165071A0 (en)	2005-12-18	The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis
GB2255093A (en)	1992-10-28	Hiv-1 core protein fragments
GR990300020T1 (en)	1999-06-30	Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg
ES2181676T3 (es)	2003-03-01	Diagnosis y tratamiento de enfermedades autoinmunitarias.
GR3024127T3 (en)	1997-10-31	Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations
PL311660A1 (en)	1996-03-04	Viral vectors and their application in genic therapy
EP0458079A3 (en)	1992-01-02	Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic
NL300156I1 (nl)	2004-09-01	Therapeutische toepassing van chimere en radioactief gemerkte antilichamen tegen humane B-Lymfocyt beperkt differentiatie antigeen voor de behandelingvan B-Cel lymfoom.
GR3035440T3 (en)	2001-05-31	Therapeutic uses of bpi protein products for human meningococcemia
ATE243750T1 (de)	2003-07-15	Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
GR3022092T3 (en)	1997-03-31	Therapeutic method for iddm.
EP0222310A3 (de)	1988-05-11	Verfahren zur Diagnose von Multiple-Sklerose
PT1025849E (pt)	2002-09-30	Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
ZA904565B (en)	1991-03-27	Peptides and antibodies derived therefrom for the diagnosis of therapy for and vaccination against htlv-1 infection
HK141494A (en)	1994-12-23	Peptide fragments of HIV
NZ515332A (en)	2004-01-30	Lawsonia derived gene and related SodC polypeptides, peptides and proteins and their uses
EP0601108A4 (en)	1997-03-19	Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects.
NZ224251A (en)	1991-09-25	Synthetic rhinovirus (hrv) peptides and vaccines
DE68918127D1 (de)	1994-10-20	Peptidbehandlung von hartnäckigen Infektionskrankheiten.
AU2065488A (en)	1989-03-23	The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent
杨春普	1988	ACUPUNCTURE OF GUANYUAN (REN 4) AND BAIHUI (DU 20) IN THE TREATMENT OF 500 CASES OF ENURESIS
SE9704451D0 (sv)	1997-11-28	New method and compositions for the treatment of autoimmune diseases